PITTSBURGH, June 6 /PRNewswire/ -- Immunetrics Inc. said it entered into a collaboration to discover inflammation biomarkers with the University of Cologne and the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology.
Under the agreement, Pittsburgh-based Immunetrics and the European partners will conduct a joint effort to discover biomarkers of inflammation with application in clinical diagnosis, in case management, and in the discovery and development of new drugs.
The agreement provides the academic partners with access to the Immunetrics modeling platform, which provides the ability to simulate the immune response in a wide range of organisms and experimental scenarios. University of Cologne is providing access to a large database of detailed human clinical data and the Ludwig Boltzmann Institute to a large database of animal model data.
"By combining these rich data sets with the Immunetrics simulation platform, the parties will increase the capability to discover important new markers of the inflammatory response through an in silico bridge that spans from animals to the clinic," said Steven Chang, chief executive officer of Pittsburgh-based Immunetrics. "We are thrilled to collaborate with these institutions and their world-renowned faculty."
In Cologne, Germany, the participation of the University of Cologne is led by Edmund Neugebauer, a global leader in trauma and sepsis. "This collaboration involves the kind of simulation and modeling technology that may be necessary to accomplish the next round of discoveries in biomarkers of inflammation," Prof. Neugebauer said.
At the Ludwig Boltzmann Institute in Vienna, the collaboration is led by Heinz Redl, a leader in preclinical models for shock and sepsis research. "We need data to drive software models and software models to simulate the data," he said. "Our collaboration provides the opportunity to accomplish this goal in the challenging field of inflammation and should offer both in silico repetition of preclinical models with varying conditions as well as integrating the exciting Immunetrics approach into daily patient monitoring."
About Immunetrics Inc.
Immunetrics is a Pittsburgh-based biosimulation company providing a platform to model complex biological systems. Immunetrics possesses the first known comprehensive model of the inflammatory response, which is now enhanced with key elements of the adaptive immune system, coagulation cascade and the arachidonic acid cascade. With this model, Immunetrics can help drug companies identify clinically relevant predictive biomarkers and prioritize and design preclinical and clinical programs for new therapies. Immunetrics was founded by LaunchCyte LLC and has been funded by Innovation Works, the University of Pittsburgh Medical Center, the University of Pittsburgh, the Pittsburgh Life Sciences Greenhouse, and individual investors.
About University of Cologne
The University of Cologne is the biggest university in Germany, including a medical faculty and a faculty of basic sciences/mathematics. There are strong collaborations between the faculties. In the field of trauma and sepsis especially the Biochemical and Experimental Department has interdisciplinary research programs with the department of applied mathematics, especially on modeling of the innate immune system in trauma and sepsis. The Biochemical and Experimental Department hosts the German Trauma Registry with currently 20,000 patients and databases in ICU with facilities in basic, experimental and clinical research. It is one of the leading departments for surgical research in Europe.
About Ludwig Boltzmann Institute for Experimental and Clinical Traumatology
The trauma center of the Austrian Workers Compensation Board integrates the Research Institute for Traumatology and the Ludwig Boltzmann Institute for Experimental und Clinical Traumatology (since 1980) is supported by the Trauma Care Consult. The institute is located in the Lorenz Bohler Trauma Hospital in Vienna, Austria. Its mission is the improvement of diagnostic and therapeutic measures in trauma surgery and intensive care by conducting research projects as well as evaluation of international research results are the basis for clinical use within the AUVA organization e.g. by clinical studies and by providing the appropriate training.